Skip to content
  • Home
  • IZB & Location
    • Laboratories and Offices
    • Start-ups at the IZB
    • Your Start-up at the IZB
    • Campus and Network
    • Management & Team
  • IZB Biotech News
    • Stories
    • Events
    • Campus
    • Region
    • Alumni News
  • Infrastructure
    • Faculty Club
    • Conference Rooms
      • Sky Room
      • Ellipse 1
      • Ellipse 2
      • Kubus
      • Ellipse 1 + 2
    • Campus-Hotel
    • Restaurants
    • BioKids
    • Chemieschule
  • Events
    • IZBrunch
    • Biotech Press Lounge
    • Pitch Day
    • Event Calendar
    • MPI: Science for everyone
  • Press & Media
    • Commemorative publication – 25 years IZB
    • IZB Brochures
    • Press
    • Press Releases
    • Media Library
    • Images
    • Videos
    • IZB in Dialog
    • Facts & Figures
  • IZB Youtube Channel
  • IZB on LinkedIN

Search

  • DE
+++ Biotech report by vfa: Biopharmaceuticals successfully gain market share +++
+++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa +++
+++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics +++
+++ Non-nutritive sweeteners may affect the human immune system +++
+++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” +++
+++ Invitris receives 250,000 EUR to complete spin-out from TUM +++
+++ Eisbach starts phase I clinical trial with COVID-19 antiviral +++
+++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park +++
+++ Specific packaging of DNA affects cell division +++
+++ Tubulis Enters Strategic Partnership with BMS +++
+++ Insempra launches its first functional component for consumer goods +++
+++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman +++
+++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease +++
+++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership +++
+++ adivo expands into new headquarters as first clinical study begins +++
+++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial +++
+++ Construction of the “New Hauner” at the Grosshadern Campus has started +++
+++ Insempra names new Chief Operating Officer +++
+++ Training events for project managers and biological safety officers +++
+++ The zebrafish brain as a map +++
+++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure +++
+++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris +++
+++ When life begins too early +++
+++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease +++
+++ Expansion of the Munich “science line” has started +++
+++ Enno Spillner to join Formycon as CFO +++
  • IZB & Location
    • Hotspot for Life Sciences
      • Offices and Laboratories
      • Your Start-up at the IZB
    • Start-ups at the IZB
    • Campus and Network
      • Weihenstephan Campus
      • Nobel prize winners on the Campus
    • Management & Team
  • Infrastructure
    • Faculty Club
    • Campus-Hotel
    • Restaurants
    • Conference Rooms
    • BioKids
    • Chemieschule
  • Events
    • IZBrunch
    • Biotech Press Lounge
    • Pitch Day
    • Event Calendar
  • Press & Media
    • Press
      • Commemorative publication – 25 years IZB
      • Facts & Figures
      • Press Releases
      • IZB at the media
      • Newsletter Registration
    • IZB Biotech News
    • Media Library
      • IZB Brochures
      • IZB in Dialog
      • Images
      • Videos

The IZB is a project of the Federal State of Bavaria

  • Contact
  • How to find us
  • IZB Hotspot & WLAN
  • Imprint
  • Privacy Policy
  • Privacy Policy Control

IZB on YouTube

IZB on linkedIn

© 2023 Innovations- und Gründerzentrum Biotechnologie IZB
  • EN
  • DE